Clinical Trial Update: Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating the efficacy and safety of an oral liquid formulation of bumetanide in children aged 2 to less than 7 with autism spectrum disorder h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• bumetanide oral liquid formulation (bumetanide)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Autism Spectrum Disorder (ASD) | Phase 3 | Status: TERMINATED | Results posted: 2023-06-05